Franklin Street Advisors Inc. NC Makes New Investment in Insulet Corporation $PODD

Franklin Street Advisors Inc. NC purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,100 shares of the medical instruments supplier’s stock, valued at approximately $346,000.

A number of other institutional investors also recently bought and sold shares of the business. Nissay Asset Management Corp Japan ADV raised its position in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after buying an additional 48 shares during the last quarter. Mather Group LLC. increased its holdings in shares of Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after purchasing an additional 48 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after purchasing an additional 52 shares in the last quarter. OLD National Bancorp IN increased its holdings in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier’s stock valued at $231,000 after purchasing an additional 55 shares in the last quarter. Finally, Cooper Financial Group increased its holdings in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 58 shares in the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Trading Down 1.0%

Shares of PODD opened at $309.11 on Friday. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm’s fifty day moving average is $321.34 and its two-hundred day moving average is $298.54. The stock has a market cap of $21.76 billion, a PE ratio of 93.95, a price-to-earnings-growth ratio of 2.59 and a beta of 1.40.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. During the same quarter in the previous year, the company posted $0.55 EPS. The firm’s quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PODD. Truist Financial began coverage on shares of Insulet in a report on Monday, June 16th. They set a “buy” rating and a $365.00 target price for the company. Canaccord Genuity Group lifted their target price on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday. Royal Bank Of Canada lifted their target price on shares of Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Wall Street Zen raised shares of Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Barclays lifted their price target on shares of Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research note on Thursday, August 21st. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $345.47.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.